newsfilter
← Latest News
Business Wire·

VBI Vaccines Reports First Quarter 2024 Financial Results

PreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from